CFAH VHIO – Vall d'Hebron Institute of Oncology

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

VHIO ‘on the ground’ at ESMO 2021: reporting advances in breast cancer treatment

19/09/2021|Comments Off on VHIO ‘on the ground’ at ESMO 2021: reporting advances in breast cancer treatment

Vall d’Hebron case study demonstrates the importance of COVID-19 vaccination in patients with malignant pleural mesothelioma

14/09/2021|Comments Off on Vall d’Hebron case study demonstrates the importance of COVID-19 vaccination in patients with malignant pleural mesothelioma

ESMO’s 2021 virtual Congress, 16 -21 September: a pick of VHIO research highlights

13/09/2021|Comments Off on ESMO’s 2021 virtual Congress, 16 -21 September: a pick of VHIO research highlights

Reporting on the European Cancer Research Summit, May 03, 2021: session summaries, take-homes & next directions

13/09/2021|Comments Off on Reporting on the European Cancer Research Summit, May 03, 2021: session summaries, take-homes & next directions

International Research Consortium Aims to Build a Reproducible Single-cell Sequencing Workflow to Capture Tumour Drug Persistence

01/09/2021|Comments Off on International Research Consortium Aims to Build a Reproducible Single-cell Sequencing Workflow to Capture Tumour Drug Persistence

Clinically qualifying predictive biomarkers of response to PARPi in patients with prostate cancer

26/08/2021|Comments Off on Clinically qualifying predictive biomarkers of response to PARPi in patients with prostate cancer

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2020

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS